Retatrutide's approximately 6-day half-life directly supports a once-weekly subcutaneous injection regimen, maintaining relatively stable plasma drug levels between doses and mirroring the dosing schedules of other long-acting incretin-based therapies such as semaglutide and tirzepatide
Retrieved 14 May 2022, from A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP)
Staying vigilant and informed empowers you to maximize the benefits of your regimen, ensuring youre not just managing your condition but thriving.
Understanding how to dose a 5mg vial properly determines whether you get results or waste your money
The mechanism is presumed to be vascular and hormonal rather than a direct drug effect
It is about precision, personalization, and longevity